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Introduction
Osteoporosis is a chronic and progressive skeletal disorder that is common in the elderly (Gennari et al., 2008) , characterized by low bone mass and weak bone strength leading to increased risk of fractures. Osteoporosis affects about 40% of post-menopausal women due to declining levels of estrogen. Selective estrogen receptor modulators (SERMs) are a class of agents that provide favorable therapeutic effects on the bone while minimizing undesirable effects of estrogens on other tissues by acting differently at the various estrogen receptors throughout the body.
Bazedoxifene acetate (BZA), a novel indole-based third generation selective estrogen receptor modulator (SERM), was selected for development for the prevention and treatment of post-menopausal osteoporosis using stringent preclinical screening parameters, including requirements for favorable effects on the bone and lipid profiles (Komm et al., 2005 , Gruber et al., 2004 , Ullrich et al., 2006 . In clinical trials, BZA has been shown to prevent bone loss, increase bone mineral density and reduce bone turnover in a two year study in post-menopausal women (Kanis 2009 and Miller et al., 2008) .
Treatment with BZA significantly reduced the incidence of new vertebral fractures in a three year study in osteoporotic post-menopausal women (Silverman et al., 2008) . BZA did not stimulate the uterine endometrium in women at dosages up to 40 mg, correlating well with the preclinical pharmacology (Miller et al., 2002; Lewiecki, et al., 2007; Ronkin et al., 2005) . BZA represents a promising pharmacotherapy against osteoporosis with a potentially enhanced safety profile (Stump et al., 2007) . Both preclinical and clinical data indicated that BZA has a unique combination of attributes, making it an DMD # 30999 attractive option for the treatment and prevention of osteoporosis (Gennari, 2007 and Gennari et al., 2008) .
BZA displayed straightforward pharmacokinetic properties following a single oral dose of [ 14 C]BZA (Chandrasekaran et al., 2009) . BZA was rapidly absorbed and the mean plasma elimination half-life of unchanged drug was long (about 33 hours). BZA was extensively metabolized in post-menopausal women through the glucuronidation pathway with few P450-mediated metabolites formed. Although conjugation takes place at both the phenyl (4′) and indole (5) moieties of the molecule, the major circulating metabolite was the indole glucuronide . Unchanged drug and BZA-4′-glucuronide were minor components in plasma. Extensive metabolism of BZA was consistent with the reported low bioavailability and high oral clearance Patat et al., 2003) indicating high first-pass effect. A long elimination half-life value and secondary peaks in the concentration-versus-time profiles also suggested that BZA underwent enterohepatic recirculation. The majority of the radioactive dose (85%) was excreted via the feces as unchanged drug, representing both unabsorbed drug and/or hydrolyzed glucuronides.
In this study, the metabolite profiles of [ 14 C]BZA were determined in cryopreserved human hepatocytes, and in hepatic and intestinal microsomes, and the UGT isozymes involved in the glucuronidation of BZA were identified by using cDNA expressed human UGT enzymes, including UGT 1A1, 1A3, 1A4, 1A6, 1A7, 1A8, 1A9, 1A10, 2B4, 2B7, 2B15 and 2B17. Kinetic parameters (K m , V max ) for the formation of BZA glucuronides were also determined in human hepatic, duodenum and jejunum microsomes, as well as 
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Methods
Chemicals and Reagents
Determination of Kinetic Parameters (K m and V max )
Incubations for the determination of kinetic parameters for the formation of BZA glucuronides by pooled female human liver, duodenum, and jejunum microsomes, and cDNA expressed human UGT1A1, 1A8 and 1A10 isoforms were performed under predetermined linear conditions with respect to time and protein concentrations. with liver (0.5 mg/mL) or intestinal (0.2 mg/mL) microsomes, or cDNA expressed UGT1A1, 1A8 and 1A10 isoforms (0.2 mg/mL) in 1.0 mL of potassium phosphate buffer (0.1 M, pH 7.4) containing 10 mM magnesium chloride and alamethicin (25 µg/mL) at 37°C up to 30 min. Due to the solubility limit in the incubation buffer, the highest concentration of BZA that could be used for the determination of kinetics was 150µM.
Reactions were initiated by the addition of UDPGA (4 mM) and were stopped by adding 1 mL of cold methanol. Proteins were removed by centrifugation and an aliquot of the extract was analyzed by HPLC. K m and V max values were calculated by a nonlinear regression method using WinNonlin software (version 5.1, Pharsight, Mountain View, CA).
Transport Experiments Across Caco-2 Cell Monolayers
Twelve-well plates with cell culture inserts (BD Biosciences, Franklin Lakes, NJ) were used for growing the cells. The cells were routinely cultured on a flask at 37°C in a humidified atmosphere of 5% CO 2 . Near confluent Caco-2 cell cultures were harvested by trypsinization with 0.25% trypsin at 37°C for 5 min and resuspended in culture medium (Dulbecco's Modified Eagle Medium (DMEM) containing 1% non-essential amino acids (NEAA), 100 unit/mL of streptomycin, 100 g/mL of penicillin, and 10% Fetal bovine serum). Caco-2 cells were seeded onto inserts at a density of 140,000 cells/cm 2 . Cell culture medium was changed every 2-3 days. After 21 days culture on the inserts, the cells were rinsed with incubation medium (DMEM with NEAA, 1% v/v) and were used for conducting studies. To determine the rates of permeation, BZA was added to either the apical or basolateral compartment at concentrations of 0.7, 7, and 70 μM. The substrate concentrations were selected based on 11 This article has not been copyedited and formatted. The final version may differ from this version. 
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the analytical sensitivity and solubility of the compound. To evaluate the involvement of P-gp, BZA (0.7 and 7 μM) was added to the apical (A) or basolateral (B) compartment in the absence or presence of verapamil (100 μM), a P-gp inhibitor. The inhibitor (verapamil) was added into both apical and basolateral compartments. All stock solutions were prepared at 20 mM in 100% DMSO and diluted in incubation medium to achieve final concentrations for studies. The maximum concentration of DMSO in the incubation medium was less than 2%. Incubations were performed in triplicates at 37C and 5% CO 2 for 2 hours in a CO 2 incubator with 40 rpm shaking. Media from the apical and basolateral compartments were collected and the radioactivity was determined using a liquid scintillation counter. 
HPLC Analysis
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increased to 40% in 25 min, 50% in 30 min, 60% in 10 min, and to 80% in 5 min, and isocratic at 80% for another 5 min.
Liquid Chromatography/Mass Spectrometry Analysis (LC/MS)
The HPLC system used for mass spectrometric analysis was an Agilent Model 1100 HPLC system equipped with a binary pump and diode array UV detector (Agilent Technologies, Palo Alto, CA). The HPLC separation conditions were as described above for metabolite profiling except that the UV detector was set to monitor 200-600 nm.
During LC/MS sample analysis, up to 10 min of the initial flow was diverted away from the mass spectrometer prior to evaluation of metabolites. The mass spectrometer used for metabolite characterization was a Finnigan LCQ Deca ion trap mass spectrometer (Thermo Electron Corp., San Jose, CA). It was equipped with an electrospray ionization (ESI) interface and operated in the positive ionization mode. The capillary temperature was 300°C, and the spray voltage was set at 4.5 kV. The nebulizer gas pressure was 90 psi and the auxiliary gas was set to 40. MS 2 analysis was performed with a relative collision energy of 30%. Synthetic BZA-4'-glucuronide and BZA-5-glucuronide standards were used to aid the structural characterization.
Data Analysis
Flo-One analytical software (version 3.60) was utilized to integrate the radioactive peaks for the quantitative calculation of metabolite formation. Xcalibur software (version 1.3, Thermo Electron Corp.) was used to control LC/MS equipment and for analysis of LC/MS data. The apparent permeability coefficient (P app ) was calculated by period. C 0 is the initial drug concentration in the donor compartment at t = 0, and A is the surface area of the monolayer. Results were expressed as a mean P app (cm/sec) ± standard deviation (SD) from three separate monolayers, unless otherwise noted. The efflux ratio (BA/AB ratio) was obtained from a ratio of P app (BA)/P app (AB). 
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Results
Metabolite Profiles in Microsomes and
Incubations with cDNA Expressed Human UGT Isozymes
To identify the UGT enzymes responsible for the formation of the two BZA glucuronides, [ 
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conjugates by UGT1A4, 1A6, and 2B17 with 81%, 100%, and 100% turnovers, respectively, indicating those UGT isozymes used in this study were metabolically active.
Glucuronidation activities of BZA for UGT isozymes are shown in Figure 4 . It should be noted that in this experiment, incubations were performed using same amount of supersomes (0.25 mg/mL protein) for each isozyme. However, the relative content of enzyme for each UGT preparation was unknown. Representative radiochromatograms of [ 14 C]BZA following incubation with UGT 1A1, 1A8 and 1A10, the three major isozymes involved in the glucuronidation of BZA, are shown in Figure 5 . BZA-4'-glucuronide formation was catalyzed most efficiently by UGT 1A1, 1A8, and 1A10, while UGT 1A3, 1A7, 1A9, 2B7 and 2B15 showed weak to moderate activity. In the formation of BZA-5-glucuronide, UGT1A1, 1A3, 1A7, 1A8, 1A9, and 1A10 displayed some activity, while UGT1A10 showed the greatest catalytic activity. UGT 1A1, 1A3, 1A7, 1A8, 1A9, and 1A10 generated both the 4'-glucuronide and 5-glucuronide, but the ratios of 4'-glucuronide to 5-glucuronide were variable and were 20, 1.6, 0.4, 8.6, 0.3, and 3.9, respectively. UGT 2B7 and 2B15 formed only the 4'-glucuronide metabolite under the experimental conditions used in this study. In these experiments, all commercially available (12) UGT isozymes were tested. However, they do not include the full complement of known UGTs. Therefore, the possible contribution of other UGT enzymes that were not tested cannot be ruled out.
In Vitro Kinetic Analysis
The kinetic parameters for the formation of 4'-glucuronide and 5-glucuronide were investigated in pooled female human liver, duodenum and jejunum microsomes and in recombinant UGT 1A1, 1A8, and 1A10; the results are summarized in Table 1 duodenum, and jejunum microsomes were 2.2, 11.8, 2.6, and 2.4-fold higher, respectively, than those for BZA-5-glucuronide, indicating that the 4'-glucuronide was formed more preferentially than the 5-glucuronide. Attempts were made to determine the kinetic parameters for the formation of bazedoxifen-5-glucuronide by UGT1A7 and UGT1A9 enzymes, but the activities appeared to be too low to calculate these parameters for these two enzymes.
Permeability of BZA and Effect of BZA Concentration and a P-gp Inhibitor on the
Transport of BZA
BZA was found to have moderate absorptive permeability (P app (AB) = 0.18 -0.73 × 10 -6 cm/sec) at the drug concentrations studied, ranging from 0.7 to 70 μM (Table 2) 
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Discussion
In the present study, the in vitro metabolism of BZA was investigated in human hepatic and intestinal microsomes and cryopreserved hepatocytes. In addition, UGT isozymes involved in the glucuronidation of BZA were identified by using cDNA expressed individual enzymes. Kinetic parameters (K m , V max ) for the formation of BZA glucuronides were also determined in microsomes and UGTs. The permeability and efflux of BZA and inhibition of P-gp were evaluated using Caco-2 monolayers.
After the incubation with BZA, two glucuronides were identified in hepatic and intestinal microsomes in the presence of UDPGA, and in human hepatocytes. Based on matching chromatographic retention times and mass spectra with those of reference standards, metabolites were identified as BZA-4'-glucuronide and BZA-5-glucuronide. BZA-4'-glucuronide was the major glucuronide formed in hepatic liver microsomes and hepatocytes, while both BZA-4'-glucuronide and BZA-5-glucuronide were the major metabolites generated in intestinal microsomes. No major oxidative metabolites were detected in microsomes in the presence of NADPH or in hepatocytes, suggesting BZA undergoes little or no P450 mediated metabolism.
UGT 1A1, 1A8, and 1A10 appear to be the three most active human UGT isoforms involved in the glucuronidation of BZA, although multiple isoforms showed some catalytic abilities. UGT1A1 efficiently converted BZA to BZA-4'-glucuronide predominantly, while UGT 1A8 and 1A10 showed relatively higher catalytic activities towards the formation of BZA-5-glucuronide than UGT1A1. UGT1A1 is known to be a major UGT enzyme expressed in the human liver (Court, 2010) , while UGT 1A8 and 1A10 are mainly expressed in the intestines (Cheng et al., 1999 and Jeong et al., 2005) .
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These data suggest that both hepatic and extrahepatic metabolism play major roles in the presystemic clearance and disposition of BZA, since BZA is converted efficiently to BZA-4'-glucuronide by both hepatic and intestinal enzymes and to BZA-5-glucuronide by intestinal enzymes.
The predominant circulating metabolite in rats and monkeys following oral administration of [ 
glucuronidation in humans (Morello, 2003 and Kemp, 2002) . As with BZA, the majority of the circulating radioactivity in post-menopausal women receiving radiolabeled raloxifene was due to a single glucuronide metabolite (raloxifene-4′-glucuronide), although it was a minor metabolite in human liver microsomes compared to the other glucuronide, raloxifene-6-glucuronide. Raloxifene-4′-glucuronide was produced in higher proportions in intestinal microsomes than raloxifene-6-glucuronide (Heringa, 2003) . In addition, UGT1A1, 1A8 and 1A10 have been found to be the primary contributors to raloxifene glucuronidation, in vitro (Kemp et al., 2002) .
In Caco-2 cell monolayer flux experiments, BZA appeared to act as a P-gp substrate, as suggested by a significant efflux ratio (>2), apparent saturation of efflux as concentration of BZA increased, and sensitivity to verapamil. On the basis of a review of absorption of drugs in human and permeability in Caco-2 monolayers, it was proposed that cm/s. Overall, this suggests moderate to high passive permeability of BZA that is likely to support good absorption. Raloxifene was also reported to be a substrate for P-gp and other transporter enzymes in the intestine (Jeong et al., 2004) . The interplay of P-gp, other transporters such as MRP, and intestinal metabolism were suggested to be important in limiting absorption of raloxifene in the intestine and in supporting enteric recycling (Jeong et al., 2004) . Taken together, the in vitro metabolism and transcellular flux data suggest that DMD # 30999 similar enzymes and pathways may be involved in the metabolism and disposition of the two SERM drugs, BZA and raloxifene in vivo. However, oral bioavailability of BZA, whilst low (6%), was found to be approximately three-fold higher than raloxifene (2%) Heringa, 2003) . An analysis of the factors that may contribute to the oral bioavailability of raloxifene suggested that intestinal glucuronidation catalysed by UGT1A8 and UGT1A10 is important in its first-pass metabolism (Mizuma, 2009 ).
Hence, it is possible that a difference in the balance of absorption, intestinal and hepatic metabolism of the two drugs underlies the difference in their bioavailability.
In conclusion, glucuronidation was the primary metabolic pathway for BZA in human in vitro systems, consistent with observations in vivo. Little P450-mediated metabolism of BZA was evident. UGT 1A1, 1A8 and 1A10 were the most active isoforms involved in the glucuronidation of BZA. Both hepatic and extra hepatic metabolism appear to play major roles in the presystemic clearance and disposition of BZA, since BZA is converted efficiently to BZA-4'-glucuronide by both hepatic and intestinal enzymes and to 5-glucuronide by intestinal enzymes. In Caco-2 cells, BZA also appeared to be a substrate for P-gp.
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